AMARIN CORP PLC\UK appointed Aaron Berg as new CEO

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Appointment of Interim CEO

On April 17, 2023, the Board of Directors (the "Board") of Amarin Corporation plc (the "Company") appointed Aaron Berg, current Executive Vice President, President-U.S. of the Company, as the Interim Chief Executive Officer and President of the Company and as the interim principal executive officer of the Company. Mr. Berg will continue to serve as Executive Vice President, President-U.S. in addition to his role as Interim Chief Executive Officer.

Mr. Berg, 60, joined the Company in November 2012 as Vice President, Marketing and Managed Care. He has since served in roles of increasing responsibility, including as Senior Vice President, Marketing and Sales from February 2014 until April 2018, as Senior Vice President and Chief Commercial Officer from April 2018 through July 2021, and currently as Executive Vice President, President-U.S., a position he has held since August 2021. Before joining the Company, Mr. Berg served as president and chief executive officer of Essentialis, Inc., a development stage pharmaceutical company, where he led the company's work on triglyceride management. Prior to joining Essentialis, Mr. Berg served as vice president of marketing and sales at Kos Pharmaceuticals, where he was instrumental in driving annual revenues approaching $1 billion until the acquisition of Kos Pharmaceuticals by Abbott Laboratories in December 2006. Mr. Berg began his pharmaceutical industry career as a sales representative with Bristol-Myers Squibb, followed by various commercial positions with Schering-Plough and GlaxoSmithKline. He obtained his B.S. in Business Management, Marketing from the University of Maryland.

In connection with Mr. Berg's becoming the Company's Interim Chief Executive Officer and President, the Company entered into a letter agreement for the provision of Mr. Berg's services (the "Agreement"). Pursuant to the Agreement, Mr. Berg will be paid an annual base salary of $700,000 per year, with his target bonus continuing to be 50% of his salary earned in his role as Executive Vice President, President-U.S., and the other terms of his employment to otherwise be consistent with the terms of his current employment agreement with the Company, which is filed as Exhibit 10.28 to the Company's Annual Report on Form 10-K for the year ended December 31, 2022.

There are no other arrangements or understandings between Mr. Berg and any other persons pursuant to which he was selected as an officer of the Company. There are also no family relationships between Mr. Berg and any director or executive officer of the Company and Mr. Berg has no direct or indirect material interest in any related party transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Appointment of Director

On April 17, 2023, the Board appointed Oliver O'Connor, 61, to the Board to a term commencing on such date. In accordance with the Company's articles of association, Mr. O'Connor will serve until the Company's 2023 annual general meeting of shareholders, when he will be a nominee for election to the Board by a vote of the Company's shareholders. Mr. O'Connor was also appointed to the Nominating and Corporate Governance Committee of the Board.

Mr. O'Connor will receive annual compensation for his service on the Board and any applicable committees, in each case, in accordance with the Company's non-employee director compensation policy, the material terms of which policy, currently in effect, are disclosed under "Item 11. Executive Compensation-Director Compensation-Non-Employee Director Compensation" of Amendment No. 1 on Form 10-K/A to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the U.S. Securities and Exchange Commission on May 2, 2022. Consistent with the current members of the Board, Mr. O'Connor has declined his initial equity award under the policy while the Board is undertaking a review of the current non-employee director compensation policy. The Company expects to enter into a deed of indemnity with Mr. O'Connor, in substantially the same form entered into with the other directors of the Company.

There are no other arrangements or understandings between Mr. O'Connor and any other person pursuant to which Mr. O'Connor was selected as a director. Mr. O'Connor is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.